The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

Matthew Hodson has decided to stand down as Executive Director of aidsmap. This marks the end of a significant era for the organisation and the HIV community. Matthew has been a formidable leader, ...

Several presentations at CROI 2024 addressed whether HIV is starting to develop resistance to the integrase inhibitor dolutegravir, one of the most widely used antiretrovirals in the world. In World ...

A high proportion of older people with HIV are taking medicines they do not need that could increase the risk of falls and confusion, Spanish researchers have found in a review of studies looking at ...

BHIVA recommends that people aged 40 and over should be offered a statin irrespective of lipid levels or estimated cardiovascular risk. People with HIV aged 40 and over with an estimated 10-year risk ...

Using a computer model, researchers at University College London have found that there is no realistic chance in the UK of reaching the 'Ending AIDS' goal for 2030 that was first set by the United ...

By 2022, half of all patients eligible for this analysis were taking reduced-drug treatment. In people taking three-drug daily treatment in 2015, there was no change in the proportion who were virally ...

In some cases, HIV can bypass the barrier that encases the brain and cerebrospinal fluid which can contribute to brain inflammation and neurocognitive symptoms. However, diagnosing this viral ‘escape’ ...